Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance.

The Lancet. Rheumatology·2026

Same author

Control of poorly immunogenic tumors with systemic STING agonist-loaded liposomes targeting cross-presenting dendritic cells.

Clinical & translational immunology·2026

Same author

Parity, body mass index, smoking and risk of rheumatoid arthritis: data from the Australian Longitudinal Study on Women's Health.

BMC rheumatology·2026

Same author

Development and preliminary evaluation of a measure ofself-efficacy of Self-Management in ARThritis: SMART.

Arthritis research & therapy·2026

Same author

The NF-κB transcription factor RelA directs mucosal-associated invariant T-cell development.

Immunology and cell biology·2026

Same author

Spatial patterning of fibroblast TGFβ signaling underlies treatment resistance in rheumatoid arthritis.

Nature immunology·2026

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Dendritic cell immunotherapy for melanoma.

Judy C Peng¹, Ranjeny Thomas, Keith Dredge

¹Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia.

Reviews on Recent Clinical Trials

|May 14, 2008

Summary

This summary is machine-generated.

Dendritic cell (DC) cancer immunotherapy shows promise but needs improvement. This review focuses on monocyte-derived DCs in melanoma trials, exploring strategies to enhance patient responses against tumors.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Experiment Videos

Last Updated: Jul 5, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating T cell-mediated anti-cancer immune responses.
DC-based cancer immunotherapy has been explored for nearly a decade, yet significant clinical breakthroughs remain elusive.
Clinical-grade DCs can be sourced from monocytes, CD34(+) progenitors, or directly from circulating blood.

Purpose of the Study:

To review the scientific basis of dendritic cell-based cancer immunotherapy.
To emphasize the application of monocyte-derived DCs in clinical trials for melanoma.
To identify potential strategies for improving patient clinical response rates in cancer immunotherapy.

Main Methods:

Review of scientific literature and clinical trial data on dendritic cell immunotherapy.
Focus on monocyte-derived dendritic cells (moDCs) and their role in melanoma treatment.
Analysis of factors influencing the efficacy of DC-based cancer vaccines.

Main Results:

Despite extensive research, DC-based immunotherapies have not consistently yielded significant anti-tumour responses.
Monocyte-derived DCs are a primary focus in current melanoma clinical trials.
Various approaches are being investigated to optimize DC immunotherapy efficacy.

Conclusions:

Dendritic cell immunotherapy holds potential for cancer treatment, particularly in melanoma.
Further research and optimization are necessary to overcome current limitations and improve patient outcomes.
Enhancing DC vaccine design and delivery strategies may lead to more effective anti-tumour responses.